Interventional treatment of multiple vascular involvement in young male with heterozygous familial

J C Lubanda1, S Simek, A Linhart

  • 12nd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, General Teaching Hospital, Prague, Czech Republic. lubanda@mail.cz

Insights

A young man with familial hypercholesterolemia and heavy smoking experienced premature atherosclerosis and acute myocardial infarction. Interventional treatments were successful, but he later died suddenly, highlighting the severe risks of combined risk factors.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Genetics

Background:

  • Familial hypercholesterolemia (FH) is a genetic disorder causing high LDL cholesterol and premature atherosclerosis.
  • Excessive tobacco use is a major risk factor for cardiovascular disease.
  • Acute myocardial infarction (MI) can be the first sign of premature atherosclerosis in young adults.

Observation:

  • A 31-year-old man with heterozygous FH and heavy smoking presented with acute MI.
  • Initial percutaneous transluminal coronary angioplasty (PTCA) of the marginal artery was successful, but LAD recanalization failed.
  • Significant left internal carotid artery stenosis and left subclavian artery occlusion were found, precluding LIMA bypass.
  • A second PTCA of the LAD and PTA of the subclavian artery were successful.

Findings:

  • Interventional methods effectively treated multiple atherosclerotic lesions, providing symptom relief.
  • Combined lipid-lowering therapy significantly reduced plasma cholesterol.
  • Despite successful interventions, the patient died suddenly two years after his initial MI.

Implications:

  • This case underscores the synergistic risk of FH and tobacco use in premature cardiovascular disease.
  • Acute physical exercise may act as a trigger for acute coronary events in susceptible individuals.
  • Aggressive management of multiple risk factors is crucial for patients with FH and premature atherosclerosis.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...